![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.50 | 0.23% | 1,529.50 | 1,531.50 | 1,532.00 | 1,541.50 | 1,523.00 | 1,537.00 | 8,077,646 | 16:35:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 12.79 | 63.05B |
Date | Subject | Author | Discuss |
---|---|---|---|
29/7/2019 14:41 | Well, cable, the culprit in this plot, could go lower. | ![]() sogoesit | |
29/7/2019 14:38 | Out at 1731 hopefully made the right call for one. Burnt out with VOD and a few others before in terms of timing. | letsmakesome | |
29/7/2019 13:54 | Yes TM you and me are in the same boat. | abdullla | |
29/7/2019 13:49 | abdullla, you are absolutely right. But for the record I made a big profit with VOD and took out all of my capital well ahead of the sale of the Verizon stake, shifting into GSK. Just look at Vodafone now - no presence in the USA, more a broadband cable and network service provider (notwithstanding a Mast company!), with little ambition to maintain a global leadership in cell phones and services. An appalling build up of debt, such that they axed the dividend. The company destroyed its business model for the worse, therefore I would no longer choose to invest in it. GSK appears to be better managed and better controlled and developing a more logical approach to improving its model, but the uncertainty is mine in so far as I find it hard to determine the future value of its potentially devolved businesses. | tradermichael | |
29/7/2019 13:13 | Usually inadviseable to bet against momentum but difficult to say whether this has enough to continue and break the 10 year "consolidation" (going nowhere) pattern. My long play is founded on the separation. I have a similar play with Reckitt Benckiser's potential separation; again with a new CEO coming along (and which also made me money with Indivior). Separation usually implies that the sum of the parts will be greater than the whole. We shall see but in any case collect 5%+ every year. | ![]() sogoesit | |
29/7/2019 13:09 | Maybe it reminds TM of the bitter old memories of Vodafone's split with VZW,ouch what a disaster that was. | abdullla | |
29/7/2019 11:47 | Yes, I will say that 1600 is the new 1500, but trading down at that level may take time especially with the next xd coming up on 8 Aug. The share really seems to have a head of steam this month, so it could be that I'll pass on the 19p this time around because it may not be an easy re-entry. Nevertheless, I still have some (£182K) that have been sitting at 1732p for a long time earning good dividends, so I'm happy either way! Unlike you, Nik, I really don't want to be in when the split takes place as I find it gets a little messy working out what the perceived market value of the two companies will be, and I prefer to let the market settle. Good luck! ……. ;0) | tradermichael | |
29/7/2019 11:25 | Well done TM. You, like me, have used the 1600 down to 1500 ploy recently. Are we resetting this to 1700 down to 1600? Personally, I am going to hold for a while longer as I haven't worked out where this is going as yet. Also I want to be in when the separation occurs. GLA. N.R. | nik rosa | |
29/7/2019 10:46 | OUT - 8579 shares @ 1712.00 …… ;0) | tradermichael | |
29/7/2019 10:20 | A lot of further coverage in the FT about M&A in the pharma sector continuing apace. Latest is merger of Pfizer and Mylan for off-patent drugs businesses. Looks like Pfizer and Glaxo are both exiting several businesses, stream-lining/slimmi FT speculates that pharma sector M&A is set to continue for some time to come. ALL IMO. DYOR. QP | ![]() quepassa | |
29/7/2019 09:03 | Hopefully it's the latter :) | letsmakesome | |
29/7/2019 08:18 | “Sellwell̶ | ![]() sogoesit | |
26/7/2019 15:13 | Long term chart and current state of markets My call is 1150p by this coming xmas dyor | ![]() buywell2 | |
26/7/2019 14:12 | Been a nice week for the longs. Here's wishing us good luck for the short term to 1710 in the next week or so. (PS: TraderMichael, I thought some EU country yields are negative now? Austria and someone had a 100-year at close to zero recently. This environment is hsitorically abnormal and, imv, artificial but will probably continue for a few years more.) | ![]() sogoesit | |
26/7/2019 09:10 | £1 = US$1.24 | tradermichael | |
26/7/2019 08:00 | The European Central Bank has opened the door to a further interest rate cut as well as additional stimulus measures as global trade tensions threaten the continent's economic outlook. It comes as the bloc struggles with a manufacturing recession particularly afflicting Germany, its largest economy. Rates are already at or around zero but in its latest monetary policy announcement the ECB raised the possibility that they could be cut further in the first half of 2020, giving up a previous pledge that they would remain unchanged. | tradermichael | |
25/7/2019 09:09 | The Lex Column in today's FT speculates that, with the disposal of the consumer division to Pfizer and subsequent reduction in size of the Group, that GSK may become an attractive target for another larger pharma company. See full FT article for context, headed: "GSK. betting the pharma". ALL IMO. DYOR. QP | ![]() quepassa | |
24/7/2019 23:58 | Cheaper rivals eat into Glaxo's profits but vaccine sales rise as drug giant ramps up spending on R&D ++ Glaxo has been hit by generic competition to its Advair inhalers in America ++ It expects earnings to fall by 3 per cent-5 per cent this year ++ Shingrix vaccine sales more than doubled in the second quarter | ![]() philanderer | |
24/7/2019 22:22 | Wow what a range ! | ![]() tim 3 | |
24/7/2019 15:07 | Looks solid enough particularly in the light of a weak market on both sides of the pond. | ![]() patientcapital | |
24/7/2019 14:41 | Glaxo (GSK) Beats Earnings & Revenue Estimates in Q2 | ![]() philanderer | |
24/7/2019 13:51 | what about the porsche driver,oh dear... | ![]() lippy4 | |
24/7/2019 13:45 | Unless you are Montyplonker the no. 1 trader who sold 2 days ago so he could "rebuy at 1600 or less" Meanwhile I have hung onto all mine... | ![]() lurker | |
24/7/2019 13:31 | Unless you're lucky, as my old dad used to say. buy and hold is the thing with a share like this, collect the dividends and keep trading costs to a minimum. | ![]() lindowcross |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions